Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.56 |
| ▸ | VCP | P55072 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 6/20 | 0.41 |
| ▸ | OGA | O60502 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | PAK4 | O96013 | 1/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581890 | 0.87 | IDH1 (0.54) | HRH4IDH1OGA | |
| SCHEMBL4581479 | 0.86 | IDH1 (0.44) | HRH4IDH1OGA | |
| SCHEMBL4580971 | 0.84 | IDH1 (0.40) | HRH4IDH1OGAMAPK13MAPK12 | |
| SCHEMBL4581007 | 0.84 | HRH4 (0.54) | HRH4IDH1OGA | |
| SCHEMBL4582251 | 0.84 | OGA (0.44) | HRH4IDH1OGAMAPK13MAPK12 | |
| SCHEMBL4580354 | 0.84 | OGA (0.55) | HRH4IDH1OGA | |
| SCHEMBL4580841 | 0.84 | IDH1 (0.42) | HRH4IDH1OGA | |
| SCHEMBL4580658 | 0.84 | IDH1 (0.44) | HRH4IDH1OGA | |
| SCHEMBL4581979 | 0.83 | IDH1 (0.53) | HRH4IDH1 | |
| SCHEMBL4581284 | 0.83 | IDH1 (0.56) | HRH4IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323464-B2 | Pyridine and pyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2008-01-29 | — | — | US | claimed |
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | GENTEX CORPORATION | 2005-04-14 | — | — | US | claimed |
| US-7323464-B2 | Pyridine and pyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2008-01-29 | — | — | US | disclosed |
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | GENTEX CORPORATION | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | ROR1, MAPK1, IRAK1 | HRH4 52/4885VCP 4877/4885IDH1 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.